
MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target
MoonLake Immunotherapeutics (MLTX) Analyst Ratings
Bulls say
MoonLake is well-positioned in the rapidly growing market for immunology drugs and has a promising pipeline with diverse indications for SLK. While there is potential for competition, the positive results from clinical trials and differentiated profile of SLK set the company apart from its peers and may lead to further growth in the future. As MoonLake continues to progress through clinical trials and potentially receive regulatory approval for SLK, it could see an increase in revenue and profitability.
Bears say
MoonLake is a clinical-stage biotechnology company with a focused pipeline in inflammatory skin and joint diseases. However, the company faces significant regulatory and competition risks in its pursuit of approval and commercialization for its lead drug candidate, sonelokimab (SLK). The company's recent equity offering and upcoming data catalysts provide near-term support and potential upside, but the development and market potential for SLK in HS and other indications may be limited by competition and diversity in the clinical landscape. All of these factors contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of MoonLake Immunotherapeutics and is not a guaranteed prediction by Public.com or investment advice.
MoonLake Immunotherapeutics (MLTX) Analyst Forecast & Price Prediction
Start investing in MoonLake Immunotherapeutics (MLTX)
Order type
Buy in
Order amount
Est. shares
0 shares